Generic Pharmaceuticals Q4 2025 Earnings: Revenue Beat, Stock Decline – News and Statistics

Mar 11, 2026

The generic pharmaceutical industry operates on a volume-driven, low-cost business model, producing bioequivalent versions of branded drugs once their patents expire. These companies benefit from consistent demand for affordable medications, as they are critical to reducing healthcare costs. Generics typically face lower R&D expenses and shorter regulatory approval timelines compared to branded drug makers, enabling cost efficiencies. However, the industry is highly competitive, with intense pricing pressures, thin margins, and frequent legal challenges from branded pharmaceutical companies over patent disputes.

The 4 generic pharmaceuticals stocks we track reported a mixed Q4. As a group, revenues beat analysts consensus estimates by 2.4%.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 12.5% since the latest earnings results.

Amneal (NASDAQ:AMRX)

Founded in 2002 and growing into one of Americas largest generic drug producers, Amneal Pharmaceuticals (NASDAQ:AMRX) develops, manufactures, and distributes generic medicines, specialty branded drugs, biosimilars, and injectable products for the U.S. healthcare market.

Amneal reported revenues of $814.3 million, up 11.5% year on year. This print exceeded analysts expectations by 0.9%. Despite the top-line beat, it was still a mixed quarter for the company with an impressive beat of analysts full-year EPS guidance estimates but full-year revenue guidance missing analysts expectations significantly.

Unsurprisingly, the stock is down 7.2% since reporting and currently trades at $13.45.

Best Q4: ANI Pharmaceuticals (NASDAQ:ANIP)

With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ:ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.

This report provides a comprehensive view of the penicillins or streptomycins medicaments industry in the United States, tracking demand, supply, and trade flows across the national value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.

Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between domestic suppliers and international partners. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the penicillins or streptomycins medicaments landscape in the United States.

Quick navigation

Key findings

• Domestic demand is shaped by both household and industrial usage, with trade flows linking local supply to imports and exports.
• Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions.
• Supply depends on input availability and production efficiency, creating a distinct national cost curve.
• Market concentration varies by segment, creating different competitive landscapes and entry barriers.
• The 2035 outlook highlights where capacity investment and demand growth are most aligned within the country.

Report scope

The report combines market sizing with trade intelligence and price analytics for the United States. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts.

• Market size and growth in value and volume terms
• Consumption structure by end-use segments
• Production capacity, output, and cost dynamics
• Trade flows, exporters, importers, and balances
• Price benchmarks, unit values, and margin signals
• Competitive context and market entry conditions

Product coverage

• Prodcom 21201160 – Medicaments of penicillins, streptomycins or derivatives thereof, in doses or p.r.s.

Country coverage

Country profile and benchmarks

This report provides a consistent view of market size, trade balance, prices, and per-capita indicators for the United States. The profile highlights demand structure and trade position, enabling benchmarking against regional and global peers.

Methodology

The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.

• International trade data (exports, imports, and mirror statistics)
• National production and consumption statistics
• Company-level information from financial filings and public releases
• Price series and unit value benchmarks
• Analyst review, outlier checks, and time-series validation

All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.

Forecasts to 2035

The forecast horizon extends to 2035 and is based on a structured model that links penicillins or streptomycins medicaments demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts in the United States.

• Historical baseline: 2012-2025
• Forecast horizon: 2026-2035
• Scenario-based sensitivity to income growth, substitution, and regulation
• Capacity and investment outlook for major producing companies

Each projection is built from national historical patterns and the broader regional context, allowing the report to show where growth is concentrated and where risks are elevated.

Price analysis and trade dynamics

Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.

• Price benchmarks by country and sub-region
• Export and import unit value trends
• Seasonality and calendar effects in trade flows
• Price outlook to 2035 under baseline assumptions

Profiles of market participants

Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.

• Business focus and production capabilities
• Geographic reach and distribution networks
• Cost structure and pricing strategy indicators
• Compliance, certification, and sustainability context

How to use this report

• Quantify domestic demand and identify the most attractive segments
• Evaluate export opportunities and prioritize target destinations
• Track price dynamics and protect margins
• Benchmark performance against leading competitors
• Build evidence-based forecasts for investment decisions

This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of penicillins or streptomycins medicaments dynamics in the United States.

FAQ

What is included in the penicillins or streptomycins medicaments market in the United States?

The market size aggregates consumption and trade data, presented in both value and volume terms.

How are the forecasts to 2035 built?

The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.

Does the report cover prices and margins?

Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.

Which benchmarks are included?

The report benchmarks market size, trade balance, prices, and per-capita indicators for the United States.

Can this report support market entry decisions?

Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.

1. 1. INTRODUCTION

   Making Data-Driven Decisions to Grow Your Business

   1. REPORT DESCRIPTION
   2. RESEARCH METHODOLOGY AND THE AI PLATFORM
   3. DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
   4. GLOSSARY AND SPECIFIC TERMS

2. 2. EXECUTIVE SUMMARY

   A Quick Overview of Market Performance

   1. KEY FINDINGS
   2. MARKET TRENDSThis Chapter is Available Only for the Professional EditionPRO

3. 3. MARKET OVERVIEW

   Understanding the Current State of The Market and its Prospects

   1. MARKET SIZE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   2. MARKET STRUCTURE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   3. TRADE BALANCE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   4. PER CAPITA CONSUMPTION: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   5. MARKET FORECAST TO 2035

4. 4. MOST PROMISING PRODUCTS FOR DIVERSIFICATION

   Finding New Products to Diversify Your Business

   1. TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
   2. BEST-SELLING PRODUCTS
   3. MOST CONSUMED PRODUCTS
   4. MOST TRADED PRODUCTS
   5. MOST PROFITABLE PRODUCTS FOR EXPORTS

5. 5. MOST PROMISING SUPPLYING COUNTRIES

   Choosing the Best Countries to Establish Your Sustainable Supply Chain

   1. TOP COUNTRIES TO SOURCE YOUR PRODUCT
   2. TOP PRODUCING COUNTRIES
   3. TOP EXPORTING COUNTRIES
   4. LOW-COST EXPORTING COUNTRIES

6. 6. MOST PROMISING OVERSEAS MARKETS

   Choosing the Best Countries to Boost Your Export

   1. TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
   2. TOP CONSUMING MARKETS
   3. UNSATURATED MARKETS
   4. TOP IMPORTING MARKETS
   5. MOST PROFITABLE MARKETS

7. 7. PRODUCTION

   The Latest Trends and Insights into The Industry

   1. PRODUCTION VOLUME AND VALUE: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)

8. 8. IMPORTS

   The Largest Import Supplying Countries

   1. IMPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   2. IMPORTS BY COUNTRY: HISTORICAL DATA (2012–2025)
   3. IMPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025)

9. 9. EXPORTS

   The Largest Destinations for Exports

   1. EXPORTS: HISTORICAL DATA (2012–2025) AND FORECAST (2026–2035)
   2. EXPORTS BY COUNTRY: HISTORICAL DATA (2012–2025)
   3. EXPORT PRICES BY COUNTRY: HISTORICAL DATA (2012–2025)

10. 10. PROFILES OF MAJOR PRODUCERS

    The Largest Producers on The Market and Their Profiles

11. LIST OF TABLES

    1. Key Findings In 2025
    2. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    3. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
    4. Per Capita Consumption: Historical Data (2012–2025) and Forecast (2026–2035)
    5. Imports, In Physical Terms, By Country, 2012–2025
    6. Imports, In Value Terms, By Country, 2012–2025
    7. Import Prices, By Country, 2012–2025
    8. Exports, In Physical Terms, By Country, 2012–2025
    9. Exports, In Value Terms, By Country, 2012–2025
    10. Export Prices, By Country, 2012–2025

12. LIST OF FIGURES

    1. Market Volume, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    2. Market Value: Historical Data (2012–2025) and Forecast (2026–2035)
    3. Market Structure – Domestic Supply vs. Imports, in Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    4. Market Structure – Domestic Supply vs. Imports, in Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    5. Trade Balance, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    6. Trade Balance, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    7. Per Capita Consumption: Historical Data (2012–2025) and Forecast (2026–2035)
    8. Market Volume Forecast to 2035
    9. Market Value Forecast to 2035
    10. Market Size and Growth, By Product
    11. Average Per Capita Consumption, By Product
    12. Exports and Growth, By Product
    13. Export Prices and Growth, By Product
    14. Production Volume and Growth
    15. Exports and Growth
    16. Export Prices and Growth
    17. Market Size and Growth
    18. Per Capita Consumption
    19. Imports and Growth
    20. Import Prices
    21. Production, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    22. Production, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    23. Imports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    24. Imports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    25. Imports, In Physical Terms, By Country, 2025
    26. Imports, In Physical Terms, By Country, 2012–2025
    27. Imports, In Value Terms, By Country, 2012–2025
    28. Import Prices, By Country, 2012–2025
    29. Exports, In Physical Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    30. Exports, In Value Terms: Historical Data (2012–2025) and Forecast (2026–2035)
    31. Exports, In Physical Terms, By Country, 2025
    32. Exports, In Physical Terms, By Country, 2012–2025
    33. Exports, In Value Terms, By Country, 2012–2025
    34. Export Prices, By Country, 2012–2025

No Byline Policy

Editorial Guidelines

Corrections Policy

Source